CEO Richard Pops was paid $7,915,081 in fiscal year 2025, ↓ down 21.9% from fiscal year 2024, the 12th percentile of its disclosed peer group (SEC filing 0001193125-26-143977 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$7,915,081 ↓ Richard Pops total, FY2025 | 12th CEO pay percentile vs peers | 30:1 CEO-to-median pay ratio | 98.73% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
ALKS's next annual pay disclosure, estimated April 5, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Richard Pops | $1,250,769 | $0 | $0 | $5,020,812 | $1,626,000 | $0 | $17,500 | $7,915,081 |
| Chief Executive Officer and Chairman of the Board | ||||||||
| Blair Jackson | 736,450 | 0 | 1,333,356 | 1,324,981 | 618,618 | 0 | 17,500 | 4,030,905 |
| Executive Vice President, Chief Operating Officer and Chief Risk Officer; Former Interim Principal Financial Officer | ||||||||
| Joshua Reed | 181,978 | 0 | 1,155,031 | 2,334,091 | 118,286 | 0 | 7,688 | 3,797,074 |
| Senior Vice President, Chief Financial Officer | ||||||||
| Craig Hopkinson | 764,837 | 0 | 1,100,001 | 1,093,107 | 642,463 | 0 | 17,500 | 3,617,908 |
| Executive Vice President, Research and Development and Chief Medical Officer | ||||||||
| David Gaffin | 684,497 | 0 | 1,100,001 | 1,093,107 | 574,978 | 0 | 17,500 | 3,470,083 |
| Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary | ||||||||
| C. Todd Nichols | 614,869 | 0 | 866,683 | 861,234 | 430,408 | 0 | 17,500 | 2,790,694 |
| Senior Vice President, Chief Commercial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Richard Pops | $7,915,081 | $10,131,193 | $9,442,066 | ↓ −2,216,112 |
| Blair Jackson | 4,030,905 | 4,891,034 | 4,561,915 | ↓ −860,129 |
| Joshua Reed | 3,797,074 | — | — | — |
| Craig Hopkinson | 3,617,908 | 4,343,991 | 4,226,388 | ↓ −726,083 |
| David Gaffin | 3,470,083 | 4,115,355 | 4,135,728 | ↓ −645,272 |
| C. Todd Nichols | 2,790,694 | 3,319,071 | — | ↓ −528,377 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Alkermes plc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ALKS reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the Alkermes plc. Peer Teardown Report
$7,915,081 Richard Pops total, FY2025
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of October 9, 2026 · Source: 0001193125-26-143977 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for ALKS
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order ALKS
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
Each company listed discloses ALKS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ALKS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Get the Alkermes plc. Executive Compensation Report
$1,500
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Brian P. McKeon | Independent Director | $491,333 |
| Cato T. Laurencin, M.D., Ph.D | Independent Director | $461,014 |
| Christopher I. Wright, M.D., Ph.D | Independent Director | $477,843 |
| David A. Daglio, Jr | Former director (through FY2025) | — |
| Emily Peterson Alva | Former director (through FY2025) | $515,258 |
| Frank Anders Wilson | Lead Independent Director | $527,234 |
| Nancy L. Snyderman, M.D | Independent Director | $479,135 |
| Nancy S. Lurker | Independent Director | $476,212 |
| Richard B. Gaynor, M.D | Independent Director | $474,014 |
| Shane M. Cooke | Independent Director | $484,751 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| David Gaffin | EVP, CLO, Alkermes, Inc. | 2026-04-06 | D | 2,034 | $35 | $70,315 | Common | Form 4 ↗ |
| Nancy S. Lurker | Director | 2026-04-11 | D | 3,751 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nancy S. Lurker | Director | 2026-04-11 | D | 901 | 33 | 30,057 | Common | Form 4 ↗ |
| Nancy S. Lurker | Director | 2026-04-11 | A | 3,751 | — | — | Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-05-01 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-05-01 | D | 9,000 | 33 | 300,560 | Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-05-01 | A | 5,000 | 19 | 96,700 | Common | Form 4 ↗ |
| David Gaffin | EVP, CLO, Alkermes, Inc. | 2026-05-04 | D | 2,034 | 33 | 67,529 | Common | Form 4 ↗ |
| Richard Gaynor | Director | 2026-05-20 | A | 5,409 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| nancy lynn snyderman MD | Director | 2026-05-20 | A | 11,538 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shane M. Cooke | Director | 2026-05-20 | A | 11,538 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Gaynor | Director | 2026-05-20 | A | 11,538 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Gaynor | Director | 2026-05-20 | A | 5,409 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Gaynor | Director | 2026-05-20 | A | 11,538 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shane M. Cooke | Director | 2026-05-20 | A | 5,409 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shane M. Cooke | Director | 2026-05-20 | A | 5,409 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shane M. Cooke | Director | 2026-05-20 | A | 11,538 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cato T. Laurencin | Director | 2026-05-20 | A | 5,409 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cato T. Laurencin | Director | 2026-05-20 | A | 11,538 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nancy S. Lurker | Director | 2026-05-20 | A | 5,409 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nancy S. Lurker | Director | 2026-05-20 | A | 11,538 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian P. McKeon | Director | 2026-05-20 | A | 5,409 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian P. McKeon | Director | 2026-05-20 | A | 11,538 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| nancy lynn snyderman MD | Director | 2026-05-20 | A | 5,409 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Anders Wilson | Director | 2026-05-20 | A | 5,409 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Anders Wilson | Director | 2026-05-20 | A | 11,538 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher I. Wright | Director | 2026-05-20 | A | 5,409 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher I. Wright | Director | 2026-05-20 | A | 11,538 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cato T. Laurencin | Director | 2026-05-21 | D | 6,142 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nancy S. Lurker | Director | 2026-05-21 | A | 6,142 | — | — | Common | Form 4 ↗ |
| nancy lynn snyderman MD | Director | 2026-05-21 | A | 6,142 | — | — | Common | Form 4 ↗ |
| Frank Anders Wilson | Director | 2026-05-21 | D | 6,142 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard Gaynor | Director | 2026-05-21 | D | 6,142 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard Gaynor | Director | 2026-05-21 | A | 6,142 | — | — | Common | Form 4 ↗ |
| Shane M. Cooke | Director | 2026-05-21 | D | 6,142 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Shane M. Cooke | Director | 2026-05-21 | A | 6,142 | — | — | Common | Form 4 ↗ |
| Richard Gaynor | Director | 2026-05-21 | D | 1,475 | 37 | 54,501 | Common | Form 4 ↗ |
| Cato T. Laurencin | Director | 2026-05-21 | D | 1,475 | 37 | 54,501 | Common | Form 4 ↗ |
| Cato T. Laurencin | Director | 2026-05-21 | A | 6,142 | — | — | Common | Form 4 ↗ |
| Nancy S. Lurker | Director | 2026-05-21 | D | 6,142 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nancy S. Lurker | Director | 2026-05-21 | D | 1,475 | 37 | 54,501 | Common | Form 4 ↗ |
| Brian P. McKeon | Director | 2026-05-21 | D | 6,142 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brian P. McKeon | Director | 2026-05-21 | D | 1,475 | 37 | 54,501 | Common | Form 4 ↗ |
| Brian P. McKeon | Director | 2026-05-21 | A | 6,142 | — | — | Common | Form 4 ↗ |
| nancy lynn snyderman MD | Director | 2026-05-21 | D | 6,142 | — | — | Derivative, Class A Common | Form 4 ↗ |
| nancy lynn snyderman MD | Director | 2026-05-21 | D | 1,475 | 37 | 54,501 | Common | Form 4 ↗ |
| Frank Anders Wilson | Director | 2026-05-21 | A | 6,142 | — | — | Common | Form 4 ↗ |
| Christopher I. Wright | Director | 2026-05-21 | D | 6,142 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christopher I. Wright | Director | 2026-05-21 | D | 1,475 | 37 | 54,501 | Common | Form 4 ↗ |
| Christopher I. Wright | Director | 2026-05-21 | A | 6,142 | — | — | Common | Form 4 ↗ |
| Shane M. Cooke | Director | 2026-05-21 | D | 3,207 | 37 | 118,499 | Common | Form 4 ↗ |
| Frank Anders Wilson | Director | 2026-05-21 | D | 1,475 | 37 | 54,501 | Common | Form 4 ↗ |
| Samuel Joseph Parisi | VP, Finance (Interim PAO) | 2026-05-29 | D | 12,825 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Samuel Joseph Parisi | VP, Finance (Interim PAO) | 2026-05-29 | A | 3,392 | 20 | 67,942 | Common | Form 4 ↗ |
| Samuel Joseph Parisi | VP, Finance (Interim PAO) | 2026-05-29 | D | 3,392 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Samuel Joseph Parisi | VP, Finance (Interim PAO) | 2026-05-29 | D | 16,217 | 42 | 687,007 | Common | Form 4 ↗ |
| Samuel Joseph Parisi | VP, Finance (Interim PAO) | 2026-05-29 | A | 12,825 | 19 | 248,036 | Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-06-01 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-06-01 | D | 9,000 | 42 | 375,044 | Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-06-01 | A | 5,000 | 19 | 96,700 | Common | Form 4 ↗ |
| David Gaffin | EVP, CLO, Alkermes, Inc. | 2026-06-04 | D | 2,034 | 43 | 87,564 | Common | Form 4 ↗ |
| Christopher I. Wright | Director | 2026-06-12 | D | 2,000 | 45 | 90,200 | Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-07-01 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-07-01 | A | 5,000 | 19 | 96,700 | Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-07-01 | D | 8,300 | 51 | 427,129 | Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-07-01 | D | 700 | 52 | 36,492 | Common | Form 4 ↗ |
| David Gaffin | EVP, CLO, Alkermes, Inc. | 2026-07-06 | D | 2,034 | 54 | 109,897 | Common | Form 4 ↗ |
| nancy lynn snyderman MD | Director | 2026-08-03 | D | 16,524 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| nancy lynn snyderman MD | Director | 2026-08-03 | A | 16,524 | 47 | 772,001 | Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-08-03 | A | 4,896 | 25 | 120,393 | Common | Form 4 ↗ |
| David Gaffin | EVP, CLO, Alkermes, Inc. | 2026-08-03 | D | 2,034 | 49 | 98,812 | Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-08-03 | D | 4,896 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-08-03 | — | 104 | — | — | 1 insider, 1 accrual row | ||
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-08-03 | D | 9,000 | 49 | 437,220 | Common | Form 4 ↗ |
| nancy lynn snyderman MD | Director | 2026-08-03 | D | 44,472 | 50 | 2,239,076 | Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-08-03 | A | 104 | 19 | 2,011 | Common | Form 4 ↗ |
| nancy lynn snyderman MD | Director | 2026-08-03 | D | 27,948 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| nancy lynn snyderman MD | Director | 2026-08-03 | A | 27,948 | 47 | 1,305,731 | Common | Form 4 ↗ |
| Blair Jackson | Director | 2026-08-05 | A | 124,305 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Blair Jackson | Director | 2026-08-05 | A | 93,229 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| C. Todd Nichols | SVP, Chief Commercial Officer | 2026-08-17 | D | 6,912 | 49 | 339,967 | Common | Form 4 ↗ |
| C. Todd Nichols | SVP, Chief Commercial Officer | 2026-08-17 | D | 664 | 50 | 32,969 | Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-09-01 | A | 5,000 | 25 | 122,950 | Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-09-01 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-09-01 | D | 9,000 | 47 | 422,874 | Common | Form 4 ↗ |
| David Gaffin | EVP, CLO, Alkermes, Inc. | 2026-09-03 | D | 2,034 | 48 | 97,652 | Common | Form 4 ↗ |
| David Gaffin | EVP, CLO, Alkermes, Inc. | 2026-10-02 | D | 2,034 | 41 | 83,455 | Common | Form 4 ↗ |
| Anne Clem Whitaker | Director | 2026-10-07 | A | 17,998 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Anne Clem Whitaker | Director | 2026-10-07 | A | 7,239 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joshua Reed | SVP, Chief Financial Officer | 2026-10-08 | D | 9,164 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joshua Reed | SVP, Chief Financial Officer | 2026-10-08 | D | 4,069 | 40 | 163,208 | Common | Form 4 ↗ |
| Joshua Reed | SVP, Chief Financial Officer | 2026-10-08 | A | 9,164 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| David Gaffin | EVP, CLO, Alkermes, Inc. | 2026-04-06 | D | 2,034 | $35 | $70,315 | Common | Form 4 ↗ |
| Nancy S. Lurker | Director | 2026-04-11 | D | 3,751 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nancy S. Lurker | Director | 2026-04-11 | D | 901 | 33 | 30,057 | Common | Form 4 ↗ |
| Nancy S. Lurker | Director | 2026-04-11 | A | 3,751 | — | — | Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-05-01 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-05-01 | D | 9,000 | 33 | 300,560 | Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-05-01 | A | 5,000 | 19 | 96,700 | Common | Form 4 ↗ |
| David Gaffin | EVP, CLO, Alkermes, Inc. | 2026-05-04 | D | 2,034 | 33 | 67,529 | Common | Form 4 ↗ |
| Richard Gaynor | Director | 2026-05-20 | A | 5,409 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| nancy lynn snyderman MD | Director | 2026-05-20 | A | 11,538 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shane M. Cooke | Director | 2026-05-20 | A | 11,538 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Gaynor | Director | 2026-05-20 | A | 11,538 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Gaynor | Director | 2026-05-20 | A | 5,409 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Gaynor | Director | 2026-05-20 | A | 11,538 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shane M. Cooke | Director | 2026-05-20 | A | 5,409 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shane M. Cooke | Director | 2026-05-20 | A | 5,409 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shane M. Cooke | Director | 2026-05-20 | A | 11,538 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cato T. Laurencin | Director | 2026-05-20 | A | 5,409 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cato T. Laurencin | Director | 2026-05-20 | A | 11,538 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nancy S. Lurker | Director | 2026-05-20 | A | 5,409 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nancy S. Lurker | Director | 2026-05-20 | A | 11,538 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian P. McKeon | Director | 2026-05-20 | A | 5,409 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian P. McKeon | Director | 2026-05-20 | A | 11,538 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| nancy lynn snyderman MD | Director | 2026-05-20 | A | 5,409 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Anders Wilson | Director | 2026-05-20 | A | 5,409 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Anders Wilson | Director | 2026-05-20 | A | 11,538 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher I. Wright | Director | 2026-05-20 | A | 5,409 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher I. Wright | Director | 2026-05-20 | A | 11,538 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cato T. Laurencin | Director | 2026-05-21 | D | 6,142 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nancy S. Lurker | Director | 2026-05-21 | A | 6,142 | — | — | Common | Form 4 ↗ |
| nancy lynn snyderman MD | Director | 2026-05-21 | A | 6,142 | — | — | Common | Form 4 ↗ |
| Frank Anders Wilson | Director | 2026-05-21 | D | 6,142 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard Gaynor | Director | 2026-05-21 | D | 6,142 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard Gaynor | Director | 2026-05-21 | A | 6,142 | — | — | Common | Form 4 ↗ |
| Shane M. Cooke | Director | 2026-05-21 | D | 6,142 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Shane M. Cooke | Director | 2026-05-21 | A | 6,142 | — | — | Common | Form 4 ↗ |
| Richard Gaynor | Director | 2026-05-21 | D | 1,475 | 37 | 54,501 | Common | Form 4 ↗ |
| Cato T. Laurencin | Director | 2026-05-21 | D | 1,475 | 37 | 54,501 | Common | Form 4 ↗ |
| Cato T. Laurencin | Director | 2026-05-21 | A | 6,142 | — | — | Common | Form 4 ↗ |
| Nancy S. Lurker | Director | 2026-05-21 | D | 6,142 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nancy S. Lurker | Director | 2026-05-21 | D | 1,475 | 37 | 54,501 | Common | Form 4 ↗ |
| Brian P. McKeon | Director | 2026-05-21 | D | 6,142 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brian P. McKeon | Director | 2026-05-21 | D | 1,475 | 37 | 54,501 | Common | Form 4 ↗ |
| Brian P. McKeon | Director | 2026-05-21 | A | 6,142 | — | — | Common | Form 4 ↗ |
| nancy lynn snyderman MD | Director | 2026-05-21 | D | 6,142 | — | — | Derivative, Class A Common | Form 4 ↗ |
| nancy lynn snyderman MD | Director | 2026-05-21 | D | 1,475 | 37 | 54,501 | Common | Form 4 ↗ |
| Frank Anders Wilson | Director | 2026-05-21 | A | 6,142 | — | — | Common | Form 4 ↗ |
| Christopher I. Wright | Director | 2026-05-21 | D | 6,142 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christopher I. Wright | Director | 2026-05-21 | D | 1,475 | 37 | 54,501 | Common | Form 4 ↗ |
| Christopher I. Wright | Director | 2026-05-21 | A | 6,142 | — | — | Common | Form 4 ↗ |
| Shane M. Cooke | Director | 2026-05-21 | D | 3,207 | 37 | 118,499 | Common | Form 4 ↗ |
| Frank Anders Wilson | Director | 2026-05-21 | D | 1,475 | 37 | 54,501 | Common | Form 4 ↗ |
| Samuel Joseph Parisi | VP, Finance (Interim PAO) | 2026-05-29 | D | 12,825 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Samuel Joseph Parisi | VP, Finance (Interim PAO) | 2026-05-29 | A | 3,392 | 20 | 67,942 | Common | Form 4 ↗ |
| Samuel Joseph Parisi | VP, Finance (Interim PAO) | 2026-05-29 | D | 3,392 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Samuel Joseph Parisi | VP, Finance (Interim PAO) | 2026-05-29 | D | 16,217 | 42 | 687,007 | Common | Form 4 ↗ |
| Samuel Joseph Parisi | VP, Finance (Interim PAO) | 2026-05-29 | A | 12,825 | 19 | 248,036 | Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-06-01 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-06-01 | D | 9,000 | 42 | 375,044 | Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-06-01 | A | 5,000 | 19 | 96,700 | Common | Form 4 ↗ |
| David Gaffin | EVP, CLO, Alkermes, Inc. | 2026-06-04 | D | 2,034 | 43 | 87,564 | Common | Form 4 ↗ |
| Christopher I. Wright | Director | 2026-06-12 | D | 2,000 | 45 | 90,200 | Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-07-01 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-07-01 | A | 5,000 | 19 | 96,700 | Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-07-01 | D | 8,300 | 51 | 427,129 | Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-07-01 | D | 700 | 52 | 36,492 | Common | Form 4 ↗ |
| David Gaffin | EVP, CLO, Alkermes, Inc. | 2026-07-06 | D | 2,034 | 54 | 109,897 | Common | Form 4 ↗ |
| nancy lynn snyderman MD | Director | 2026-08-03 | D | 16,524 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| nancy lynn snyderman MD | Director | 2026-08-03 | A | 16,524 | 47 | 772,001 | Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-08-03 | A | 4,896 | 25 | 120,393 | Common | Form 4 ↗ |
| David Gaffin | EVP, CLO, Alkermes, Inc. | 2026-08-03 | D | 2,034 | 49 | 98,812 | Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-08-03 | D | 4,896 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-08-03 | D | 104 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-08-03 | D | 9,000 | 49 | 437,220 | Common | Form 4 ↗ |
| nancy lynn snyderman MD | Director | 2026-08-03 | D | 44,472 | 50 | 2,239,076 | Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-08-03 | A | 104 | 19 | 2,011 | Common | Form 4 ↗ |
| nancy lynn snyderman MD | Director | 2026-08-03 | D | 27,948 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| nancy lynn snyderman MD | Director | 2026-08-03 | A | 27,948 | 47 | 1,305,731 | Common | Form 4 ↗ |
| Blair Jackson | Director | 2026-08-05 | A | 124,305 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Blair Jackson | Director | 2026-08-05 | A | 93,229 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| C. Todd Nichols | SVP, Chief Commercial Officer | 2026-08-17 | D | 6,912 | 49 | 339,967 | Common | Form 4 ↗ |
| C. Todd Nichols | SVP, Chief Commercial Officer | 2026-08-17 | D | 664 | 50 | 32,969 | Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-09-01 | A | 5,000 | 25 | 122,950 | Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-09-01 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Craig Hopkinson | EVP R&D, Chief Medical Officer | 2026-09-01 | D | 9,000 | 47 | 422,874 | Common | Form 4 ↗ |
| David Gaffin | EVP, CLO, Alkermes, Inc. | 2026-09-03 | D | 2,034 | 48 | 97,652 | Common | Form 4 ↗ |
| David Gaffin | EVP, CLO, Alkermes, Inc. | 2026-10-02 | D | 2,034 | 41 | 83,455 | Common | Form 4 ↗ |
| Anne Clem Whitaker | Director | 2026-10-07 | A | 17,998 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Anne Clem Whitaker | Director | 2026-10-07 | A | 7,239 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joshua Reed | SVP, Chief Financial Officer | 2026-10-08 | D | 9,164 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joshua Reed | SVP, Chief Financial Officer | 2026-10-08 | D | 4,069 | 40 | 163,208 | Common | Form 4 ↗ |
| Joshua Reed | SVP, Chief Financial Officer | 2026-10-08 | A | 9,164 | — | — | Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Craig Hopkinson | OPTION | 2025-02-19 | — | — | 63,991 | — | $1,093,107 |
| Blair Jackson | RSU | 2025-02-19 | — | — | 37,203 | — | 1,333,356 |
| Blair Jackson | OPTION | 2025-02-19 | — | — | 77,565 | — | 1,324,981 |
| C. Todd Nichols | RSU | 2025-02-19 | — | — | 24,182 | — | 866,683 |
| Joshua Reed | OPTION | 2025-10-08 | — | — | 158,743 | — | 2,334,091 |
| C. Todd Nichols | OPTION | 2025-02-19 | — | — | 50,417 | — | 861,234 |
| Joshua Reed | RSU | 2025-10-08 | — | — | 36,656 | — | 1,155,031 |
| David Gaffin | RSU | 2025-02-19 | — | — | 30,692 | — | 1,100,001 |
| Craig Hopkinson | RSU | 2025-02-19 | — | — | 30,692 | — | 1,100,001 |
| Richard Pops | OPTION | 2025-02-19 | — | — | 293,921 | — | 5,020,812 |
| David Gaffin | OPTION | 2025-02-19 | — | — | 63,991 | — | 1,093,107 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Craig Hopkinson | $1,100,001 | $0 | $1,093,107 | 0.0% |
| Blair Jackson | 1,333,356 | 0 | 1,324,981 | 0.0% |
| C. Todd Nichols | 866,683 | 0 | 861,234 | 0.0% |
| Joshua Reed | 1,155,031 | 0 | 2,334,091 | 0.0% |
| David Gaffin | 1,100,001 | 0 | 1,093,107 | 0.0% |
| Richard Pops | 0 | 0 | 5,020,812 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Richard Pops | PSU | 119,228 | — | $3,335,999 |
| David Gaffin | PSU | 23,019 | — | 644,072 |
| Richard Pops | RSU | 149,580 | — | 4,185,248 |
| Blair Jackson | RSU | 28,810 | — | 806,104 |
| C. Todd Nichols | RSU | 24,182 | — | 676,612 |
| Richard Pops | PSU | 127,205 | — | 3,559,196 |
| Blair Jackson | RSU | 24,967 | — | 698,577 |
| C. Todd Nichols | RSU | 21,127 | — | 591,133 |
| Richard Pops | RSU | 63,602 | — | 1,779,584 |
| Craig Hopkinson | RSU | 30,692 | — | 858,762 |
| Blair Jackson | RSU | 37,203 | — | 1,040,940 |
| Joshua Reed | RSU | 36,656 | — | 1,025,635 |
| David Gaffin | RSU | 30,692 | — | 858,762 |
| David Gaffin | PSU | 20,598 | — | 576,332 |
| Blair Jackson | PSU | 27,902 | — | 780,698 |
| David Gaffin | RSU | 25,352 | — | 709,349 |
| Blair Jackson | RSU | 17,476 | — | 488,978 |
| Richard Pops | Option | 293,921 | 35.84 | — |
| Craig Hopkinson | RSU | 25,352 | — | 709,349 |
| Blair Jackson | Option | 77,565 | 35.84 | — |
| Craig Hopkinson | RSU | 20,598 | — | 576,332 |
| Craig Hopkinson | PSU | 20,598 | — | 576,332 |
| Blair Jackson | PSU | 24,967 | — | 698,577 |
| C. Todd Nichols | RSU | 6,355 | — | 177,813 |
| Blair Jackson | Option | 35,586 | 24.59 | — |
| Craig Hopkinson | Option | 63,991 | 35.84 | — |
| Craig Hopkinson | PSU | 23,019 | — | 644,072 |
| Craig Hopkinson | RSU | 8,897 | — | 248,938 |
| Richard Pops | Option | 145,285 | 26.82 | — |
| C. Todd Nichols | RSU | 12,815 | — | 358,564 |
| David Gaffin | RSU | 20,598 | — | 576,332 |
| Craig Hopkinson | RSU | 10,299 | — | 288,166 |
| Blair Jackson | Option | 69,902 | 26.82 | — |
| C. Todd Nichols | Option | 25,419 | 24.59 | — |
| C. Todd Nichols | PSU | 18,136 | — | 507,445 |
| C. Todd Nichols | RSU | 16,229 | — | 454,087 |
| Blair Jackson | RSU | 12,483 | — | 349,274 |
| C. Todd Nichols | PSU | 16,288 | — | 455,738 |
| Craig Hopkinson | RSU | 15,379 | — | 430,304 |
| Richard Pops | Option | 76,256 | 24.59 | — |
| C. Todd Nichols | Option | 50,417 | 35.84 | — |
| David Gaffin | RSU | 15,379 | — | 430,304 |
| David Gaffin | RSU | 10,299 | — | 288,166 |
| Richard Pops | Option | 205,746 | 30.04 | — |
| David Gaffin | Option | 61,514 | 26.82 | — |
| Blair Jackson | RSU | 8,897 | — | 248,938 |
| C. Todd Nichols | RSU | 8,114 | — | 227,030 |
| David Gaffin | RSU | 6,355 | — | 177,813 |
| David Gaffin | RSU | 2,015 | — | 56,380 |
| Joshua Reed | Option | 158,743 | 31.51 | — |
| David Gaffin | Option | 7,347 | 24.82 | — |
| Blair Jackson | Option | 101,079 | 30.04 | — |
| David Gaffin | Option | 25,419 | 24.59 | — |
| David Gaffin | Option | 83,390 | 30.04 | — |
| David Gaffin | Option | 63,991 | 35.84 | — |
| Craig Hopkinson | Option | 35,586 | 24.59 | — |
| Craig Hopkinson | Option | 61,514 | 26.82 | — |
| Craig Hopkinson | Option | 83,390 | 30.04 | — |
| C. Todd Nichols | Option | 51,261 | 26.82 | — |
| C. Todd Nichols | Option | 65,702 | 30.04 | — |
The executive compensation program is focused on attracting and retaining experienced and well-qualified executive officers who will help advance critical business objectives and rewarding them for performance that contributes meaningfully to the creation of shareholder value. The program structures a significant proportion of compensation as performance-based to align pay with performance and shareholder interests, while maintaining market competitiveness through peer comparisons.
| CEO STI target (% of salary) | 150% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-20 | 139,234,176 | 1,787,311 | 148,488 | 98.73% | Passed |
| 2025 | 2025-05-21 | 143,326,743 | 1,891,000 | 893,115 | 98.7% | Passed |
| 2024 | 2024-05-31 | 149,795,702 | 2,358,534 | 504,188 | 98.45% | Passed |
| 2023 | 2023-06-29 | 115,881,199 | 30,815,867 | 289,712 | 78.99% | Passed |
| 2022 | 2022-07-07 | 126,034,510 | 19,942,736 | 92,246 | 86.34% | Passed |
| 2021 | 2021-06-14 | 93,167,886 | 35,087,053 | 206,132 | 72.64% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-20 | 98.73%a |
| 2025 | 2025-05-21 | 98.7%b |
| 2024 | 2024-05-31 | 98.45%c |
a. Approved under the standard stated in the filing — “Abstentions and broker-non votes (if any) will have no effect on the outcome of this proposal, as they are not considered to be votes cast.”.
b. Approved under the standard stated in the filing — “Abstentions and broker-non votes (if any) will have no effect on the outcome of this proposal, as they are not considered to be votes cast.”.
c. Approved under the standard stated in the filing — “Abstentions and broker-non votes (if any) will have no effect on the outcome of this proposal, as they are not considered to be votes cast.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 30 : 1 |
|---|---|
| CEO total compensation | $7,936,648 |
| Median employee compensation | $266,757 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Frank Anders WilsonIndependent · Lead Independent Director · Audit and Risk · Nominating and Corporate Governance | $152,220 | $187,515 | $187,499 | — | $0 | $527,234 |
| David A. Daglio JrIndependent · Not standing for re-election · Departed during FY | 39,401 | 250,567 | 226,461 | 0 | 0 | 516,429 |
| Emily Peterson AlvaIndependent · Not standing for re-election · Departed during FY | 38,230 | 250,567 | 226,461 | — | 0 | 515,258 |
| Brian P. McKeonIndependent · Compensation · Nominating and Corporate Governance | 116,319 | 187,515 | 187,499 | — | 0 | 491,333 |
| Shane M. CookeIndependent · Audit and Risk (Chair) · Nominating and Corporate Governance | 109,737 | 187,515 | 187,499 | — | 0 | 484,751 |
| Nancy L. Snyderman, M.DIndependent · Audit and Risk · Financial Operating | 104,121 | 187,515 | 187,499 | — | 0 | 479,135 |
| Christopher I. Wright, M.D., Ph.DIndependent · Audit and Risk · Compensation | 102,829 | 187,515 | 187,499 | — | 0 | 477,843 |
| Nancy S. LurkerIndependent · Compensation · Nominating and Corporate Governance (Chair) | 101,198 | 187,515 | 187,499 | — | 0 | 476,212 |
| Richard B. Gaynor, M.DIndependent · Compensation (Chair) | 99,000 | 187,515 | 187,499 | — | 0 | 474,014 |
| Cato T. Laurencin, M.D., Ph.DIndependent · Financial Operating | 86,000 | 187,515 | 187,499 | — | 0 | 461,014 |
| Richard F. PopsEmployee director · Board Chair · Financial Operating | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $74,000 |
|---|---|
| Annual equity retainer | $375,000 |
| Per board meeting fee | $3,500 |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 25,000 / 20,000 |
| Stock ownership guideline | $3 |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $949,055 |
| Equity awards (grant-date value) | $2,001,254 |
| All other compensation | $0 |
| Total cost of the board | $2,950,309 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Alkermes plc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Alkermes plc..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | Incyte | 2025 | William Meury | 647,260 | 27,509,657 | 2,573,998 | 1,300,000 | 32,085,952 |
| 3 | PTC Therapeutics | 2025 | Matthew Klein | 958,500 | 16,593,800 | 4,399,760 | 1,294,000 | 23,266,326 |
| 4 | Halozyme Therapeutics | 2025 | Helen Torley | 1,000,000 | 19,350,145 | 1,650,014 | 1,147,500 | 23,166,223 |
| 5 | BioMarin Pharmaceutical | 2025 | Alexander Hardy | 1,130,769 | 16,833,629 | 1,909,310 | 1,644,500 | 21,927,563 |
| 6 | Jazz Pharmaceuticals | 2025 | Renee Gala | 1,003,269 | 16,138,433 | 0 | 1,980,000 | 19,151,558 |
| 7 | United Therapeutics | 2025 | Martine Rothblatt | 1,545,005 | 6,067,990 | 6,075,804 | 4,281,875 | 18,038,972 |
| 8 | Blueprint Medicines | 2024 | Kathryn Haviland | 821,363 | 7,472,480 | 4,315,144 | 854,217 | 13,477,004 |
| 9 | Neurocrine Biosciences | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 10 | Ionis Pharmaceuticals | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 11 | Ultragenyx Pharmaceutical | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 12 | Axsome Therapeutics | 2025 | Herriot Tabuteau | 835,000 | 5,533,554 | 2,833,237 | 876,750 | 10,283,492 |
| 13 | Intra-Cellular Therapies | 2023 | Sharon Mates | 891,653 | 7,749,984 | 0 | 0 | 10,086,413 |
| 14 | Acadia Pharmaceuticals | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 15 | Alkermes plc. | 2025 | Richard Pops | 1,250,769 | 0 | 5,020,812 | 1,626,000 | 7,915,081 |
| 16 | Harmony Biosciences | 2025 | Jeffrey Dayno | 743,600 | 1,976,520 | 4,599,000 | 558,000 | 7,899,535 |
| 17 | Sarepta Therapeutics | 2025 | Douglas Ingram | 1,171,425 | 6,000,005 | 0 | 649,000 | 7,840,666 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Alkermes plc. | 130% | PRSU 53 · RSU 24 · Option 23 | Yes — Relative Total Shareholder Return (TSR) | Alpine Rewards LLC |
| Acadia Pharmaceuticals | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Axsome Therapeutics | 150% | RSU 33 · Options 33 · PSU 33 | No | Frederic W. Cook & Co., Inc. |
| BioMarin Pharmaceutical | 130% | PSU 66 · RSU 21 · Options 13 | Yes — Relative TSR | Aon Human Capital Solutions |
| Blueprint Medicines | 130% | RSU 37 · Options 32 · PSU 31 | Yes — Relative Total Stockholder Return (rTSR) | Aon |
| Exelixis | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Halozyme Therapeutics | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| Harmony Biosciences | 100% | not disclosed | not disclosed | Pay Governance |
| Incyte | 138.6% | Performance Shares 60 · RSU 40 | Yes — relative total shareholder return (TSR) | Aon |
| Intra-Cellular Therapies | not disclosed | RSU 75 · PRSU 25 | Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology Index | Aon Consulting, Inc. |
| Ionis Pharmaceuticals | not disclosed | PRSU 40 · Option 30 · RSU 30 | Yes — Relative TSR | Aon |
| Jazz Pharmaceuticals | 150% | PSU 50 · RSU 50 | Yes — Relative TSR | Aon |
| Neurocrine Biosciences | 105% | Options 50 · PSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| PTC Therapeutics | not disclosed | Option 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | Frederic W. Cook & Co., Inc. |
| Sarepta Therapeutics | 100% | PSU 50 · Option 25 · RSU 25 | No | FW Cook |
| Ultragenyx Pharmaceutical | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
| United Therapeutics | 221% | PSO 50 · PSU 50 | No | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Richard Pops | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “EXECUTIVE COMPENSATION TABLES” · page 106. As printed: 7,915,081. Filing ↗machine: r3 · c33 · span 2508258–2508267 |
| 2 | Section 01, Blair Jackson | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “EXECUTIVE COMPENSATION TABLES” · page 106. As printed: 4,030,905. Filing ↗machine: r8 · c33 · span 2571116–2571125 |
| 3 | Section 01, Joshua Reed | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “EXECUTIVE COMPENSATION TABLES” · page 106. As printed: 3,797,074. Filing ↗machine: r6 · c33 · span 2548123–2548132 |
| 4 | Section 01, Craig Hopkinson | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “EXECUTIVE COMPENSATION TABLES” · page 106. As printed: 3,617,908. Filing ↗machine: r14 · c33 · span 2650583–2650592 |
| 5 | Section 01, David Gaffin | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “EXECUTIVE COMPENSATION TABLES” · page 106. As printed: 3,470,083. Filing ↗machine: r11 · c33 · span 2610849–2610858 |
| 6 | Section 01, C. Todd Nichols | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “EXECUTIVE COMPENSATION TABLES” · page 106. As printed: 2,790,694. Filing ↗machine: r17 · c33 · span 2690295–2690304 |
| 7 | Section 03, Craig Hopkinson OPTION | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t119 · r14 · c17 · span 2644790–2644799 |
| 8 | Section 03, Blair Jackson RSU | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t119 · r8 · c13 · span 2563873–2563882 |
| 9 | Section 03, Blair Jackson OPTION | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t119 · r8 · c17 · span 2565323–2565332 |
| 10 | Section 03, C. Todd Nichols RSU | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t119 · r17 · c13 · span 2683056–2683063 |
| 11 | Section 03, Joshua Reed OPTION | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t119 · r6 · c17 · span 2542331–2542340 |
| 12 | Section 03, C. Todd Nichols OPTION | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t119 · r17 · c17 · span 2684504–2684511 |
| 13 | Section 03, Joshua Reed RSU | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t119 · r6 · c13 · span 2540881–2540890 |
| 14 | Section 03, David Gaffin RSU | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t119 · r11 · c13 · span 2603606–2603615 |
| 15 | Section 03, Craig Hopkinson RSU | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “ALKERMES PLC” · grants of plan-based awards table. Filing ↗machine: t119 · r14 · c13 · span 2643340–2643349 |
| 16 | Section 03, Richard Pops OPTION | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t119 · r3 · c17 · span 2502463–2502472 |
| 17 | Section 03, David Gaffin OPTION | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t119 · r11 · c17 · span 2605056–2605065 |
| 18 | Section 07, pay ratio | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “CEO Pay Ratio”. As printed: 30 : 1. Filing ↗machine: span 4726278–4726280 |
| 19 | Section 08, Frank Anders Wilson | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “Director Compensation”. As printed: 527,234. Filing ↗machine: span 1078780–1079007 |
| 20 | Section 08, David A. Daglio Jr | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “Director Compensation”. As printed: 516,429. Filing ↗machine: span 1037400–1037627 |
| 21 | Section 08, Emily Peterson Alva | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “Director Compensation”. As printed: 515,258. Filing ↗machine: span 1023615–1023842 |
| 22 | Section 08, Brian P. McKeon | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “Director Compensation”. As printed: 491,333. Filing ↗machine: span 1064985–1065212 |
| 23 | Section 08, Shane M. Cooke | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “Director Compensation”. As printed: 484,751. Filing ↗machine: span 1030505–1030732 |
| 24 | Section 08, Nancy L. Snyderman, M.D | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “Director Compensation”. As printed: 479,135. Filing ↗machine: span 1071885–1072112 |
| 25 | Section 08, Christopher I. Wright, M.D., Ph.D | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “Director Compensation”. As printed: 477,843. Filing ↗machine: span 1085690–1085917 |
| 26 | Section 08, Nancy S. Lurker | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “Director Compensation”. As printed: 476,212. Filing ↗machine: span 1058094–1058321 |
| 27 | Section 08, Richard B. Gaynor, M.D | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “Director Compensation”. As printed: 474,014. Filing ↗machine: span 1044298–1044525 |
| 28 | Section 08, Cato T. Laurencin, M.D., Ph.D | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “Director Compensation”. As printed: 461,014. Filing ↗machine: span 1051203–1051430 |
| 29 | Section 08, Richard F. Pops | DEF 14A | 2026-04-06 | 0001193125-26-143977 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 30 | Section 02, David Gaffin 2026-04-06 | Form 4 | 2026-04-06 | 0001520262-26-000067 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Nancy S. Lurker 2026-04-11 | Form 4 | 2026-04-13 | 0001520262-26-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Nancy S. Lurker 2026-04-11 | Form 4 | 2026-04-13 | 0001520262-26-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Nancy S. Lurker 2026-04-11 | Form 4 | 2026-04-13 | 0001520262-26-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Craig Hopkinson 2026-05-01 | Form 4 | 2026-05-01 | 0001520262-26-000072 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Craig Hopkinson 2026-05-01 | Form 4 | 2026-05-01 | 0001520262-26-000072 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Craig Hopkinson 2026-05-01 | Form 4 | 2026-05-01 | 0001520262-26-000072 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, David Gaffin 2026-05-04 | Form 4 | 2026-05-04 | 0001520262-26-000074 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Richard Gaynor 2026-05-20 | Form 4 | 2026-05-22 | 0001520262-26-000087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, nancy lynn snyderman MD 2026-05-20 | Form 4 | 2026-05-22 | 0001520262-26-000091 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Shane M. Cooke 2026-05-20 | Form 4 | 2026-05-22 | 0001520262-26-000083 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Richard Gaynor 2026-05-20 | Form 4 | 2026-05-22 | 0001520262-26-000087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Richard Gaynor 2026-05-20 | Form 4 | 2026-05-22 | 0001520262-26-000084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Richard Gaynor 2026-05-20 | Form 4 | 2026-05-22 | 0001520262-26-000084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Shane M. Cooke 2026-05-20 | Form 4 | 2026-05-22 | 0001520262-26-000083 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Shane M. Cooke 2026-05-20 | Form 4 | 2026-05-22 | 0001520262-26-000086 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Shane M. Cooke 2026-05-20 | Form 4 | 2026-05-22 | 0001520262-26-000086 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Cato T. Laurencin 2026-05-20 | Form 4 | 2026-05-22 | 0001520262-26-000088 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Cato T. Laurencin 2026-05-20 | Form 4 | 2026-05-22 | 0001520262-26-000088 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Nancy S. Lurker 2026-05-20 | Form 4 | 2026-05-22 | 0001520262-26-000089 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Nancy S. Lurker 2026-05-20 | Form 4 | 2026-05-22 | 0001520262-26-000089 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Brian P. McKeon 2026-05-20 | Form 4 | 2026-05-22 | 0001520262-26-000090 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Brian P. McKeon 2026-05-20 | Form 4 | 2026-05-22 | 0001520262-26-000090 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, nancy lynn snyderman MD 2026-05-20 | Form 4 | 2026-05-22 | 0001520262-26-000091 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Frank Anders Wilson 2026-05-20 | Form 4 | 2026-05-22 | 0001520262-26-000092 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Frank Anders Wilson 2026-05-20 | Form 4 | 2026-05-22 | 0001520262-26-000092 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Christopher I. Wright 2026-05-20 | Form 4 | 2026-05-22 | 0001520262-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Christopher I. Wright 2026-05-20 | Form 4 | 2026-05-22 | 0001520262-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Cato T. Laurencin 2026-05-21 | Form 4 | 2026-05-22 | 0001520262-26-000088 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Nancy S. Lurker 2026-05-21 | Form 4 | 2026-05-22 | 0001520262-26-000089 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, nancy lynn snyderman MD 2026-05-21 | Form 4 | 2026-05-22 | 0001520262-26-000091 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Frank Anders Wilson 2026-05-21 | Form 4 | 2026-05-22 | 0001520262-26-000092 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Richard Gaynor 2026-05-21 | Form 4 | 2026-05-22 | 0001520262-26-000084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Richard Gaynor 2026-05-21 | Form 4 | 2026-05-22 | 0001520262-26-000084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Shane M. Cooke 2026-05-21 | Form 4 | 2026-05-22 | 0001520262-26-000083 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Shane M. Cooke 2026-05-21 | Form 4 | 2026-05-22 | 0001520262-26-000083 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Richard Gaynor 2026-05-21 | Form 4 | 2026-05-22 | 0001520262-26-000084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Cato T. Laurencin 2026-05-21 | Form 4 | 2026-05-22 | 0001520262-26-000088 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Cato T. Laurencin 2026-05-21 | Form 4 | 2026-05-22 | 0001520262-26-000088 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Nancy S. Lurker 2026-05-21 | Form 4 | 2026-05-22 | 0001520262-26-000089 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Nancy S. Lurker 2026-05-21 | Form 4 | 2026-05-22 | 0001520262-26-000089 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Brian P. McKeon 2026-05-21 | Form 4 | 2026-05-22 | 0001520262-26-000090 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Brian P. McKeon 2026-05-21 | Form 4 | 2026-05-22 | 0001520262-26-000090 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Brian P. McKeon 2026-05-21 | Form 4 | 2026-05-22 | 0001520262-26-000090 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, nancy lynn snyderman MD 2026-05-21 | Form 4 | 2026-05-22 | 0001520262-26-000091 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, nancy lynn snyderman MD 2026-05-21 | Form 4 | 2026-05-22 | 0001520262-26-000091 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Frank Anders Wilson 2026-05-21 | Form 4 | 2026-05-22 | 0001520262-26-000092 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Christopher I. Wright 2026-05-21 | Form 4 | 2026-05-22 | 0001520262-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Christopher I. Wright 2026-05-21 | Form 4 | 2026-05-22 | 0001520262-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Christopher I. Wright 2026-05-21 | Form 4 | 2026-05-22 | 0001520262-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Shane M. Cooke 2026-05-21 | Form 4 | 2026-05-22 | 0001520262-26-000083 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Frank Anders Wilson 2026-05-21 | Form 4 | 2026-05-22 | 0001520262-26-000092 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Samuel Joseph Parisi 2026-05-29 | Form 4 | 2026-05-29 | 0001520262-26-000095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Samuel Joseph Parisi 2026-05-29 | Form 4 | 2026-05-29 | 0001520262-26-000095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Samuel Joseph Parisi 2026-05-29 | Form 4 | 2026-05-29 | 0001520262-26-000095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Samuel Joseph Parisi 2026-05-29 | Form 4 | 2026-05-29 | 0001520262-26-000095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Samuel Joseph Parisi 2026-05-29 | Form 4 | 2026-05-29 | 0001520262-26-000095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Craig Hopkinson 2026-06-01 | Form 4 | 2026-06-01 | 0001520262-26-000097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Craig Hopkinson 2026-06-01 | Form 4 | 2026-06-01 | 0001520262-26-000097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Craig Hopkinson 2026-06-01 | Form 4 | 2026-06-01 | 0001520262-26-000097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, David Gaffin 2026-06-04 | Form 4 | 2026-06-04 | 0001520262-26-000099 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Christopher I. Wright 2026-06-12 | Form 4 | 2026-06-12 | 0001520262-26-000101 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Craig Hopkinson 2026-07-01 | Form 4 | 2026-07-01 | 0001520262-26-000103 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Craig Hopkinson 2026-07-01 | Form 4 | 2026-07-01 | 0001520262-26-000103 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Craig Hopkinson 2026-07-01 | Form 4 | 2026-07-01 | 0001520262-26-000103 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Craig Hopkinson 2026-07-01 | Form 4 | 2026-07-01 | 0001520262-26-000103 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, David Gaffin 2026-07-06 | Form 4 | 2026-07-06 | 0001520262-26-000105 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, nancy lynn snyderman MD 2026-08-03 | Form 4 | 2026-08-03 | 0001520262-26-000111 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, nancy lynn snyderman MD 2026-08-03 | Form 4 | 2026-08-03 | 0001520262-26-000111 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Craig Hopkinson 2026-08-03 | Form 4 | 2026-08-03 | 0001520262-26-000110 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, David Gaffin 2026-08-03 | Form 4 | 2026-08-03 | 0001520262-26-000109 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Craig Hopkinson 2026-08-03 | Form 4 | 2026-08-03 | 0001520262-26-000110 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Craig Hopkinson 2026-08-03 | Form 4 | 2026-08-03 | 0001520262-26-000110 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Craig Hopkinson 2026-08-03 | Form 4 | 2026-08-03 | 0001520262-26-000110 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, nancy lynn snyderman MD 2026-08-03 | Form 4 | 2026-08-03 | 0001520262-26-000111 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Craig Hopkinson 2026-08-03 | Form 4 | 2026-08-03 | 0001520262-26-000110 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, nancy lynn snyderman MD 2026-08-03 | Form 4 | 2026-08-03 | 0001520262-26-000111 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, nancy lynn snyderman MD 2026-08-03 | Form 4 | 2026-08-03 | 0001520262-26-000111 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Blair Jackson 2026-08-05 | Form 4 | 2026-08-07 | 0001520262-26-000113 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Blair Jackson 2026-08-05 | Form 4 | 2026-08-07 | 0001520262-26-000113 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, C. Todd Nichols 2026-08-17 | Form 4 | 2026-08-17 | 0001520262-26-000116 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, C. Todd Nichols 2026-08-17 | Form 4 | 2026-08-17 | 0001520262-26-000116 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Craig Hopkinson 2026-09-01 | Form 4 | 2026-09-01 | 0001520262-26-000118 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Craig Hopkinson 2026-09-01 | Form 4 | 2026-09-01 | 0001520262-26-000118 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Craig Hopkinson 2026-09-01 | Form 4 | 2026-09-01 | 0001520262-26-000118 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, David Gaffin 2026-09-03 | Form 4 | 2026-09-03 | 0001520262-26-000120 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, David Gaffin 2026-10-02 | Form 4 | 2026-10-02 | 0001520262-26-000127 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, Anne Clem Whitaker 2026-10-07 | Form 4 | 2026-10-09 | 0001520262-26-000130 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, Anne Clem Whitaker 2026-10-07 | Form 4 | 2026-10-09 | 0001520262-26-000130 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, Joshua Reed 2026-10-08 | Form 4 | 2026-10-09 | 0001520262-26-000131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, Joshua Reed 2026-10-08 | Form 4 | 2026-10-09 | 0001520262-26-000131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, Joshua Reed 2026-10-08 | Form 4 | 2026-10-09 | 0001520262-26-000131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 06, 2026 vote | Form 8-K | 2026-05-20 | 0001193125-26-232584 | Item 5.07 · say-on-pay result. As reported: 98.73% (votes for as printed: 139,234,176). Filing ↗ |
| 123 | Section 06, 2025 vote | Form 8-K | 2025-05-21 | 0000950170-25-075783 | Item 5.07 · say-on-pay result. As reported: 98.7% (votes for as printed: 143,326,743). Filing ↗ |
| 124 | Section 06, 2024 vote | Form 8-K | 2024-05-31 | 0000950170-24-067296 | Item 5.07 · say-on-pay result. As reported: 98.45% (votes for as printed: 149,795,702). Filing ↗ |
| 125 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 126 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 127 | Section 09b board cost (computed) | Computed | — | — | Cash 949,055 + equity 2,001,254 + all other 0 = 2,950,309, summed across the director compensation table rows.machine: formula: Σ = 2,950,309 |
| 128 | Exelixis, Section 10b CEO total | DEF 14A | 2026-04-15 | 0000939767-26-000046 | CEO total compensation as printed in Exelixis's own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526 |
| 129 | Incyte, Section 10b CEO total | DEF 14A | 2026-04-28 | 0000879169-26-000031 | CEO total compensation as printed in Incyte's own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827 |
| 130 | PTC Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-20 | 0001104659-26-045528 | CEO total compensation as printed in PTC Therapeutics's own proxy. As printed: 23,266,326. Filing ↗ |
| 131 | Halozyme Therapeutics, Section 10b CEO total | DEF 14A | 2026-03-23 | 0001159036-26-000041 | CEO total compensation as printed in Halozyme Therapeutics's own proxy. As printed: 23,166,223. Filing ↗machine: r3 · c48 · span 478282–478292 |
| 132 | BioMarin Pharmaceutical, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001628280-26-026290 | CEO total compensation as printed in BioMarin Pharmaceutical's own proxy. As printed: 21,927,563. Filing ↗machine: span 1384905–1384915 |
| 133 | Jazz Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-06-08 | 0001232524-26-000029 | CEO total compensation as printed in Jazz Pharmaceuticals's own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379 |
| 134 | United Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001082554-26-000009 | CEO total compensation as printed in United Therapeutics's own proxy. As printed: 18,038,972. Filing ↗machine: span 1993726–1993736 |
| 135 | Blueprint Medicines, Section 10b CEO total | DEF 14A | 2025-04-24 | 0001558370-25-005415 | CEO total compensation as printed in Blueprint Medicines's own proxy. As printed: 13,477,004. Filing ↗machine: span 1101152–1101162 |
| 136 | Neurocrine Biosciences, Section 10b CEO total | DEF 14A | 2026-04-15 | 0000914475-26-000015 | CEO total compensation as printed in Neurocrine Biosciences's own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957 |
| 137 | Ionis Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001140361-26-016388 | CEO total compensation as printed in Ionis Pharmaceuticals's own proxy. As printed: 13,350,777. Filing ↗ |
| 138 | Ultragenyx Pharmaceutical, Section 10b CEO total | DEF 14A | 2026-03-27 | 0001308179-26-000174 | CEO total compensation as printed in Ultragenyx Pharmaceutical's own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007 |
| 139 | Axsome Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177610 | CEO total compensation as printed in Axsome Therapeutics's own proxy. As printed: 10,283,492. Filing ↗machine: t51 · r2 · c27 · span 900236–900246 |
| 140 | Intra-Cellular Therapies, Section 10b CEO total | DEF 14A | 2024-04-29 | 0001628280-24-018986 | CEO total compensation as printed in Intra-Cellular Therapies's own proxy. As printed: 10,086,413. Filing ↗machine: r2 · c39 · span 440593–440603 |
| 141 | Acadia Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174163 | CEO total compensation as printed in Acadia Pharmaceuticals's own proxy. As printed: 8,256,518. Filing ↗ |
| 142 | Alkermes plc. (subject), Section 10b CEO total | DEF 14A | 2026-04-06 | 0001193125-26-143977 | CEO total compensation as printed in Alkermes plc.'s own proxy. As printed: 7,915,081. Filing ↗machine: r3 · c33 · span 2508258–2508267 |
| 143 | Harmony Biosciences, Section 10b CEO total | DEF 14A | 2026-04-03 | 0001104659-26-039449 | CEO total compensation as printed in Harmony Biosciences's own proxy. As printed: 7,899,535. Filing ↗machine: t108 · r5 · c16 · span 580355–580364 |
| 144 | Sarepta Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177247 | CEO total compensation as printed in Sarepta Therapeutics's own proxy. As printed: 7,840,666. Filing ↗machine: span 1454395–1454404 |
| 145 | Section 10a, Acadia Pharmaceuticals reciprocity | DEF 14A | — | 0001193125-26-174163 | Acadia Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Alkermes plc.. Filing ↗ |
| 146 | Section 10a, Axsome Therapeutics reciprocity | DEF 14A | — | 0001193125-26-177610 | Axsome Therapeutics's most recent proxy was read; its disclosed peer group does not include Alkermes plc.. Filing ↗ |
| 147 | Section 10a, BioMarin Pharmaceutical reciprocity | DEF 14A | — | 0001628280-26-026290 | BioMarin Pharmaceutical's most recent proxy was read; its disclosed peer group does not include Alkermes plc.. Filing ↗ |
| 148 | Section 10a, Blueprint Medicines reciprocity | DEF 14A | — | 0001558370-25-005415 | Blueprint Medicines names Alkermes plc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 149 | Section 10a, Exelixis reciprocity | DEF 14A | — | 0000939767-26-000046 | Exelixis names Alkermes plc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 150 | Section 10a, Halozyme Therapeutics reciprocity | DEF 14A | — | 0001159036-26-000041 | Halozyme Therapeutics names Alkermes plc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 151 | Section 10a, Harmony Biosciences reciprocity | DEF 14A | — | 0001104659-26-039449 | Harmony Biosciences names Alkermes plc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 152 | Section 10a, Ionis Pharmaceuticals reciprocity | DEF 14A | — | 0001140361-26-016388 | Ionis Pharmaceuticals names Alkermes plc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 153 | Section 10a, Jazz Pharmaceuticals reciprocity | DEF 14A | — | 0001232524-26-000029 | Jazz Pharmaceuticals names Alkermes plc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 154 | Section 10a, PTC Therapeutics reciprocity | DEF 14A | — | 0001104659-26-045528 | PTC Therapeutics names Alkermes plc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 155 | Section 10a, Sarepta Therapeutics reciprocity | DEF 14A | — | 0001193125-26-177247 | Sarepta Therapeutics names Alkermes plc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 156 | Section 10a, Ultragenyx Pharmaceutical reciprocity | DEF 14A | — | 0001308179-26-000174 | Ultragenyx Pharmaceutical names Alkermes plc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 157 | Section 10a, United Therapeutics reciprocity | DEF 14A | — | 0001082554-26-000009 | United Therapeutics names Alkermes plc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 158 | Section 10a, Intra-Cellular Therapies reciprocity | DEF 14A | — | 0001628280-24-018986 | Intra-Cellular Therapies's most recent proxy was read; its disclosed peer group does not include Alkermes plc.. Filing ↗ |
| 159 | Section 10a, Neurocrine Biosciences reciprocity | DEF 14A | — | 0000914475-26-000015 | Neurocrine Biosciences names Alkermes plc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the Alkermes plc. Executive Compensation Report
$1,500